Department of General Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Thromb Res. 2011 Nov;128(5):403-9. doi: 10.1016/j.thromres.2011.07.014. Epub 2011 Aug 9.
Testing for genetic risks of Factor V Leiden ( FVL ) in inflammatory bowel disease (IBD) patients with thromboembolism (TE) is common, but the safety and utility of such testing need review.
The aim of the present study was to investigate whether the FVL polymorphisms would be one inherited prothrombotic risk factor that could significantly increase the risk of thrombosis in patients with IBD.
We performed an electronic databases search to identify published studies correlating the FVL mutations with four populations including one IBD group with TE complications, one control IBD group without TE complications, one control non-IBD group with TE complications and another healthy control (HC) group. Statistical analysis was performed with Review Manager (RevMan) 5.0. Sub-analysis/sensitivity analysis was also performed.
We identified 112 titles and included 22 studies in this meta-analysis. The odds ratio (OR) of TE in IBD patients with FVL was higher as compared with IBD patients (OR: 4.00; 95%CI: 2.04, 7.87) and HC (OR: 3.19; 95%CI: 1.38, 7.36). There was a 1.25-fold (95%CI: 0.90-1.74) increase in incidence of FVL gene mutation in IBD patients compared with HC. The FVL mutations were not significantly different between IBD patients with thrombosis and non-IBD patients with thrombosis (OR: 0.79; 95%CI: 0.43, 1.47).
FVL plays a role in IBD-TE, but to no greater extent than it does in the general population with TE.
在患有血栓栓塞症 (TE) 的炎症性肠病 (IBD) 患者中检测因子 V 莱顿 (FVL) 的遗传风险很常见，但需要对这种检测的安全性和实用性进行审查。
本研究旨在探讨 FVL 多态性是否为一种遗传性促血栓形成的危险因素，可显著增加 IBD 患者发生血栓的风险。
我们进行了电子数据库搜索，以确定与四个群体相关的已发表研究，包括一个 IBD 组伴有 TE 并发症、一个无 TE 并发症的对照 IBD 组、一个伴有 TE 并发症的对照非 IBD 组和另一个健康对照组 (HC)。使用 Review Manager (RevMan) 5.0 进行统计分析。还进行了亚分析/敏感性分析。
我们确定了 112 个标题，并将 22 项研究纳入了这项荟萃分析。与 IBD 患者（比值比 [OR]：4.00；95%可信区间 [CI]：2.04，7.87）和 HC（OR：3.19；95%CI：1.38，7.36）相比，FVL 阳性的 IBD 患者发生 TE 的几率更高。与 HC 相比，IBD 患者的 FVL 基因突变发生率增加了 1.25 倍（95%CI：0.90-1.74）。FVL 基因突变在 IBD 伴血栓形成患者与非 IBD 伴血栓形成患者之间无显著差异（OR：0.79；95%CI：0.43，1.47）。
FVL 在 IBD-TE 中起作用，但与 TE 一般人群相比，作用不大。
